Hormone Replacement Therapy for Women: 4 Hormone Targets, 3 Delivery Methods, 1 Lab-Confirmed Protocol

Table of Contents

1. What Hormone Replacement Therapy for Women Is
2. How Hormones Decline and Why It Matters: The Perimenopause and Menopause Transition
3. The 4 Hormone Targets: Estrogen, Progesterone, Testosterone, and DHEA
4. 3 Delivery Methods: How Elizabeth Chooses the Right One
5. Who Is a Candidate for HRT
6. The Protocol: Labs First, Then Treatment
7. Results and What Changes After Starting HRT
8. Costs and What the Protocol Includes
9. The Rebuild Regen Approach to Women's Hormone Health
10. Is Hormone Replacement Therapy the Right Choice for Your Symptoms?
11. Frequently Asked Questions
12. When HRT Is Contraindicated or Requires Modification

---

What Hormone Replacement Therapy for Women Is

Hormone replacement therapy for women is a physician-managed protocol that restores declining estrogen, progesterone, and sometimes testosterone levels in women experiencing perimenopause, menopause, or hormonal imbalance through bioidentical or synthetic hormone supplementation.

The word "replacement" in the name describes the core action: when the body's natural hormone production declines, HRT restores those levels to a therapeutic range that supports normal physiological function. This is not enhancement or augmentation. It is restoration of hormones that the body produced naturally in younger years but no longer produces at adequate levels.

HRT is one of the most studied interventions in women's medicine. The evidence base spans decades and has been significantly refined since early studies created confusion about risks and benefits. The modern understanding of HRT, particularly bioidentical hormone protocols, is substantially more favorable than the picture painted by older data, especially when treatment begins within 10 years of menopause onset and is managed by a clinician who reviews labs and adjusts protocols based on individual response.

Elizabeth Celestin, APRN, FNP-C, manages women's hormone health at Rebuild Regen Medical Clinic. Her approach is anchored in laboratory confirmation of hormone levels before any protocol is initiated. She does not prescribe HRT based on symptom description alone. Labs establish the baseline, and the protocol is built on what the data shows.

---

How Hormones Decline and Why It Matters: The Perimenopause and Menopause Transition

Hormone replacement therapy for women addresses a biological process that begins years before menopause is clinically defined and continues for decades afterward. Understanding the timeline helps explain why timing of HRT initiation matters and what symptoms correspond to which hormonal changes.

Perimenopause: The Transition Phase

Perimenopause typically begins in a woman's early to mid-40s, though it can start earlier. During this phase, ovarian function begins to fluctuate. Estrogen production becomes erratic, cycling between higher-than-normal and lower-than-normal levels within a single menstrual cycle. Progesterone levels begin a more consistent decline as ovulation becomes less regular.

The hormonal fluctuation of perimenopause produces characteristic symptoms:

• Irregular menstrual cycles (shorter, longer, heavier, or lighter)
• Sleep disturbances, often waking at 2 to 4 AM
• Hot flashes and night sweats that begin in the perimenopausal window, sometimes years before menopause
• Mood changes: irritability, anxiety, and brain fog linked to estrogen fluctuation
• Breast tenderness driven by estrogen surges
• Worsening PMS symptoms linked to progesterone decline

Many women in perimenopause are told their labs are "normal" because estrogen may still be in the normal range on a given day. The problem is the fluctuation, not a permanently low level. Progesterone is often clinically low during perimenopause even when estrogen appears adequate.

Menopause: The Clinical Definition and Beyond

Menopause is clinically defined as 12 consecutive months without a menstrual period. The average age of natural menopause in the United States is 51 to 52. After menopause, ovarian estrogen production drops significantly. Estradiol (the primary active form of estrogen) falls from premenopausal levels of 100 to 400 pg/mL to post-menopausal levels typically below 20 pg/mL.

This sharp decline produces the hallmark menopausal symptoms: hot flashes and night sweats, vaginal dryness and urinary changes, significant sleep disruption, bone density loss, cardiovascular risk changes, and cognitive effects including word retrieval difficulties and concentration changes.

Postmenopause extends for the remainder of a woman's life. Without intervention, the estrogen-deficient state persists, and the associated health effects accumulate over time, including accelerating bone density loss, increasing cardiovascular risk, and cognitive health consequences.

Surgical Menopause

Women who have undergone hysterectomy with bilateral oophorectomy experience abrupt surgical menopause regardless of age. The sudden cessation of ovarian hormone production creates more acute symptoms than the gradual perimenopausal transition. Women in surgical menopause often experience more severe HRT needs and require prompt initiation of hormone support.

---

The 4 Hormone Targets: Estrogen, Progesterone, Testosterone, and DHEA

Hormone replacement therapy for women at Rebuild Regen addresses up to four hormones depending on what laboratory testing reveals.

1. Estrogen (Estradiol)

Estradiol (E2) is the primary estrogen addressed in HRT. It is the most biologically active of the three estrogens (estradiol, estrone, estriol) and is responsible for most of the physiological functions associated with estrogen: bone density maintenance, cardiovascular protection, brain function, skin health, vaginal tissue integrity, and libido.

In HRT protocols, estradiol is the primary hormone being replaced. Bioidentical estradiol is chemically identical to the estradiol produced by the ovaries. Synthetic estrogens (conjugated equine estrogens) are derived from equine sources and have a different receptor binding profile.

The laboratory target for estradiol replacement depends on the patient's symptoms and health goals, but generally the aim is to restore levels sufficient to address symptoms without exceeding physiologically normal premenopausal ranges.

2. Progesterone

Progesterone serves multiple roles in women's health beyond pregnancy support. It is neuroprotective (supports sleep quality and reduces anxiety), protective of the uterine lining (critical for any woman with an intact uterus receiving estrogen), and counterbalances some of estrogen's proliferative effects on tissue.

For women with an intact uterus, progesterone must be prescribed alongside estrogen to prevent endometrial hyperplasia. Bioidentical progesterone (as opposed to synthetic progestins) has a distinct safety and tolerability profile. Synthetic progestins, including medroxyprogesterone acetate (MPA), were associated with increased breast cancer risk in the Women's Health Initiative study. Bioidentical micronized progesterone does not carry the same findings.

Women who have had a hysterectomy may not require progesterone for uterine protection, but may still benefit from its neuroprotective and sleep-supporting properties depending on their symptom picture.

3. Testosterone

Testosterone is not exclusively a male hormone. Women produce testosterone in the ovaries and adrenal glands, and it plays a significant role in female physiology: libido, energy, muscle maintenance, cognitive function, and mood. Testosterone levels decline through perimenopause and menopause along with estrogen and progesterone.

Low testosterone in women is frequently under-recognized because it is not routinely tested and is not FDA-approved as an indication for female HRT. Yet it is clinically meaningful. Women with persistently low libido, fatigue unresponsive to estrogen and progesterone correction, difficulty maintaining muscle mass, or cognitive sluggishness despite adequate E2 and progesterone replacement often show subnormal free testosterone levels on comprehensive hormone panels.

Low-dose testosterone supplementation for women is a well-established practice in functional and integrative medicine, even without an FDA-indicated product for female testosterone therapy in the US. Elizabeth Celestin discusses testosterone testing and the clinical rationale for its inclusion in the protocol when lab results and symptoms support it.

4. DHEA

Dehydroepiandrosterone (DHEA) is a precursor hormone produced by the adrenal glands that converts into both estrogen and testosterone in peripheral tissues. DHEA levels peak in early adulthood and decline progressively with age. Low DHEA is associated with fatigue, reduced immune function, decreased bone density, and reduced precursor availability for sex hormone production.

DHEA supplementation is used as a supporting element in some hormone protocols, particularly for women whose testosterone and estrogen deficits are partly driven by low DHEA substrate. Vaginal DHEA (prasterone) is FDA-approved for dyspareunia associated with menopause and is used as a topical option for vaginal tissue restoration.

---

3 Delivery Methods: How Elizabeth Chooses the Right One

The delivery method for HRT affects hormone absorption, stability of levels, convenience, and side effect profile. Elizabeth Celestin selects the delivery method based on the specific hormones being replaced, the patient's lifestyle, personal preferences, and the clinical goal.

Method 1: Bioidentical Hormone Pellets

Pellet therapy involves inserting small, compressed hormone pellets (typically about the size of a grain of rice) subcutaneously in the hip or buttock area under local anesthesia. The pellets dissolve gradually over 3 to 5 months, releasing hormones at a consistent rate throughout the day.

Advantages:

• Consistent, steady hormone levels without the peaks and troughs of other methods
• No daily compliance requirement (forget a pill or miss a cream application and pellets continue releasing regardless)
• Activity-responsive: pellet release increases slightly with increased blood flow during exercise, mimicking natural hormone release patterns
• 3 to 5 month interval between insertions

Considerations:

• Pellet doses cannot be adjusted once inserted; dosing accuracy upfront is important
• Minor insertion procedure required under local anesthesia
• Generally considered the most expensive delivery method

Pellet therapy is frequently the preferred approach for women seeking estradiol and testosterone replacement simultaneously with the convenience of quarterly treatment.

Method 2: Injections

Intramuscular or subcutaneous hormone injections deliver estradiol cypionate or testosterone cypionate on a weekly or biweekly schedule. Patients can self-administer after training, or visit the clinic.

Advantages:

• Adjustable dosing; levels can be fine-tuned at each follow-up
• Cost-effective compared to pellet therapy
• Rapid dose changes possible if side effects emerge or labs show adjustments are needed

Considerations:

• Weekly or biweekly administration schedule
• Some patients experience mild level fluctuations between doses
• Injection site management required

Injections are commonly used for testosterone in women and for patients who prefer flexibility in dose adjustment.

Method 3: Topical (Creams, Gels, Patches)

Transdermal estrogen and progesterone are available as creams, gels, and patches applied to the skin daily. The hormone is absorbed through the skin and enters the bloodstream without first-pass liver metabolism.

Advantages:

• Avoids liver first-pass metabolism (reduces some risks associated with oral hormones)
• Gentle, gradual absorption
• Patches provide consistent daily delivery; creams and gels allow flexible application

Considerations:

• Daily application required
• Skin absorption can be inconsistent based on application site, skin condition, and individual variability
• Transfer risk with creams (contact with children or partners if not managed correctly)

Topical progesterone cream is frequently used as a gentler supplemental approach for women who need primarily progesterone support with less estrogen adjustment needed.

The right delivery method is not universal. The consultation with Elizabeth Celestin includes a discussion of the patient's lifestyle, preferences, and the specific hormone combination required to determine which delivery method serves the protocol best.

---

Who Is a Candidate for HRT

Hormone replacement therapy for women is appropriate for a broad range of patients experiencing hormone-related symptoms confirmed by laboratory testing.

Strong candidates include:

• Women in perimenopause with irregular cycles, sleep disturbance, hot flashes, or mood changes combined with lab-confirmed hormonal fluctuation
• Women in menopause experiencing vasomotor symptoms (hot flashes, night sweats), vaginal dryness, sleep disruption, or cognitive changes
• Women with surgical menopause following oophorectomy
• Women with premature ovarian insufficiency (POI) before age 40
• Women with documented low testosterone contributing to fatigue, libido changes, or cognitive sluggishness
• Women with bone density loss (osteopenia) in the context of estrogen deficiency

Relative considerations that affect protocol design:

• Personal or family history of breast cancer: HRT decisions in women with BRCA mutations or personal breast cancer history require careful risk-benefit discussion. Not all such women are excluded, but the protocol and hormone selection may differ.
• History of deep vein thrombosis or clotting disorders: Oral estrogens increase thrombotic risk; transdermal estrogen does not carry the same risk profile. Route selection becomes critical.
• Cardiovascular disease: HRT initiation early in menopause (within 10 years of onset or before age 60) is associated with cardiovascular protection. Initiating HRT in older postmenopausal women with established cardiovascular disease requires more individualized assessment.
• Unexplained uterine bleeding: Must be evaluated before HRT initiation.

The consultation reviews each patient's full medical history, family history, and current lab panel before any hormone protocol is designed.

---

The Protocol: Labs First, Then Treatment

No hormone protocol at Rebuild Regen is initiated without a complete hormone panel. Elizabeth Celestin's approach is anchored in objective data, not symptom description alone.

The Initial Lab Panel

Baseline labs for women's HRT evaluation include:

• Estradiol (E2)
• Progesterone (timed appropriately in cycle if still cycling)
• Total and free testosterone
• DHEA-S
• FSH and LH (pituitary hormones that rise as ovarian function declines; elevated FSH is a primary marker of menopausal transition)
• Sex hormone binding globulin (SHBG), which affects free hormone availability
• Thyroid panel (TSH, free T3, free T4) — thyroid dysfunction mimics many menopausal symptoms
• Complete metabolic panel (liver and kidney function)
• Lipid panel
• CBC

Protocol Design

After reviewing the lab panel, Elizabeth Celestin designs a protocol addressing the specific hormone deficits identified. The protocol specifies:

• Which hormones are being replaced
• The delivery method for each
• The dose for each hormone
• The monitoring schedule

Monitoring and Adjustment

Follow-up labs are drawn at 4 to 6 weeks after protocol initiation and at each 3-month interval. Doses are adjusted based on lab results and symptom response. The goal is to achieve therapeutic hormone levels that resolve symptoms without exceeding the upper range of normal premenopausal levels.

Long-term monitoring includes annual labs, periodic breast health screening, and bone density tracking as appropriate for the patient's age and risk profile.

---

Results and What Changes After Starting HRT

Women who start HRT with appropriately designed protocols based on their specific hormone deficits typically experience meaningful symptom improvement within 4 to 12 weeks.

Vasomotor symptoms (hot flashes, night sweats): These are among the first to respond. Most women report significant reduction in frequency and intensity within 4 to 8 weeks of reaching therapeutic estradiol levels.

Sleep: Sleep quality often improves before other symptoms, as progesterone's neurological effects support deeper sleep stages. Women who have been waking at 2 to 4 AM with night sweats typically experience improved sleep continuity within weeks of progesterone and estradiol correction.

Mood and cognitive function: Brain fog, word retrieval difficulties, and irritability associated with estrogen fluctuation improve as levels stabilize. Some women describe this as "coming back to themselves." The timeline is typically 6 to 12 weeks.

Vaginal and urinary symptoms: Vaginal dryness, discomfort during intercourse, and urinary urgency related to estrogen deficiency improve with appropriate topical or systemic estrogen. Local vaginal estrogen is often added even when systemic therapy is in use, as systemic levels may not fully restore vaginal tissue.

Energy and libido: Testosterone correction drives improvements in energy, motivation, and libido. Women often notice libido and exercise performance improvements within 6 to 8 weeks of testosterone correction.

Bone density: Estrogen's protective effect on bone density takes longer to show measurably. Bone density scans are repeated at 2-year intervals to track the protective effect of HRT.

Cardiovascular protection: The "timing hypothesis" in HRT research supports early initiation of estrogen therapy as protective for cardiovascular health. Women who start HRT within 10 years of menopause onset show better cardiovascular outcomes than those who start later.

---

Costs and What the Protocol Includes

Women's HRT pricing at Rebuild Regen depends on the specific hormones being replaced and the delivery method selected.

Pellet therapy involves a procedure fee per insertion (quarterly or twice-yearly depending on the protocol) plus the hormone compounds. Injection and topical protocols are priced based on the products prescribed and the monitoring visits.

All pricing is transparent at consultation. Exact costs are provided after the initial lab panel review and protocol design.

What is included:

• Initial consultation with Elizabeth Celestin
• Lab order and results review
• Protocol design with specific hormone selection and dosing
• Administration of the chosen delivery method (pellet insertion, injection, or prescription for topical)
• Follow-up labs and monitoring visits
• Ongoing dose adjustments as needed

Standard health insurance covers some lab work. Hormone products and administration fees are typically self-pay. Medical financing is available.

---

The Rebuild Regen Approach to Women's Hormone Health

Elizabeth Celestin's background in emergency and trauma medicine informs her clinical approach to hormone management. ER medicine demands pattern recognition under pressure and comfort with physiological complexity. Those skills translate directly to hormonal medicine, where multiple systems interact and symptom patterns require careful parsing.

Her approach to women's HRT is specific:

• No protocol without labs. Symptoms guide the clinical picture, but dosing is based on data.
• Bioidentical preference. Where a bioidentical option exists with equivalent efficacy, it is used.
• Testosterone is not ignored. Female testosterone deficiency is under-treated in conventional medicine. Elizabeth includes it in the evaluation routinely.
• DHEA is part of the picture. Adrenal contribution to sex hormone production is assessed alongside ovarian production.
• Thyroid is always checked. Thyroid dysfunction mimics perimenopausal and menopausal symptoms closely. Treating a thyroid problem as a hormone deficiency (or vice versa) produces poor outcomes.

The integration of HRT with the broader regenerative medicine offerings at Rebuild Regen means that women with hormone-related musculoskeletal changes, such as joint pain and tendon vulnerability that worsen with estrogen deficiency, can address the hormonal root cause and receive targeted regenerative treatment simultaneously.

---

Is Hormone Replacement Therapy the Right Choice for Your Symptoms?

The evaluation question for HRT is whether the symptoms driving the consultation are hormone-mediated and whether the lab panel confirms the deficits that explain them.

Women who present with a full perimenopausal or menopausal symptom constellation and lab-confirmed estrogen and progesterone decline are clear candidates. The decision is primarily about timing, protocol design, and delivery method.

Women who present with symptoms that could be hormonal but whose labs show normal ranges require more careful evaluation. The consultation explores whether thyroid dysfunction, adrenal fatigue, nutritional deficiencies, or metabolic issues are contributing alongside or instead of the hormonal picture. Elizabeth Celestin treats the whole clinical picture, not just the most convenient diagnosis.

Women with symptom profiles suggesting hormonal deficiency who have relative contraindications (cancer history, clotting history, cardiovascular disease) are not automatically excluded. The risk-benefit discussion is individualized based on the specific history, the specific contraindication, and the availability of modified protocols that reduce risk while addressing the hormonal need.

---

Frequently Asked Questions

What are the symptoms of low estrogen?

Low estrogen produces hot flashes, night sweats, vaginal dryness, sleep disruption, brain fog, mood changes including irritability and anxiety, joint pain, skin thinning, and urinary urgency or frequency. These symptoms overlap with other conditions, which is why lab confirmation is essential before attributing them to estrogen deficiency and initiating HRT.

Is bioidentical HRT safer than synthetic HRT?

Bioidentical hormones are chemically identical to the hormones produced by the human body, which means they interact with hormone receptors exactly as endogenous hormones do. Synthetic progestins (like medroxyprogesterone acetate in the Women's Health Initiative study) have a different receptor binding profile and a different safety data set. The current evidence supports bioidentical progesterone as having a more favorable safety profile than synthetic progestins. Bioidentical estradiol delivered transdermally does not carry the same thrombotic risk as oral conjugated estrogens.

Do I need progesterone if I have had a hysterectomy?

Women without a uterus do not require progesterone for endometrial protection, since the uterus is not present. However, progesterone has physiological effects beyond uterine protection, including neurological support, sleep quality improvement, and anxiety reduction. Elizabeth Celestin evaluates the full symptom picture, and some women who have had hysterectomies still benefit clinically from progesterone inclusion in their protocol.

How long does it take for HRT to work?

The first symptoms to improve are typically vasomotor (hot flashes, night sweats) and sleep, usually within 4 to 8 weeks of reaching therapeutic levels. Mood, energy, and cognitive improvements follow over 6 to 12 weeks. Libido and physical changes with testosterone correction are typically noticed at 6 to 10 weeks. Some changes, including bone density protection and cardiovascular benefits, are longer-term effects measured over months to years.

Can I start HRT if I am in perimenopause and still having periods?

Perimenopause is an appropriate time to begin addressing hormone deficits. Progesterone supplementation is frequently indicated during perimenopause when ovulation is irregular and progesterone production is insufficient. Estrogen supplementation may be used at lower doses to reduce the erratic fluctuation that produces symptoms. The protocol during perimenopause differs from full menopause replacement, and monitoring is adjusted accordingly.

Does HRT cause weight gain?

The relationship between HRT and weight is frequently misunderstood. Menopause itself is associated with fat redistribution from the periphery to the abdomen due to estrogen decline. Properly managed HRT that restores estrogen to therapeutic levels tends to support a more favorable body composition than untreated menopause. Some patients notice fluid retention early in the protocol that resolves as levels stabilize. The clinical reality for most patients is that HRT supports easier weight management, not the opposite.

How often are labs required on HRT?

Labs are drawn at baseline before protocol initiation, at 4 to 6 weeks after starting treatment, at 3 months, and then every 6 to 12 months for ongoing monitoring. Dose adjustments are based on lab results and symptom response. Annual comprehensive panels including lipid, metabolic, and hormonal markers are part of long-term monitoring.

What is the difference between pellet therapy and injections for women?

Pellet therapy provides continuous, steady hormone release over 3 to 5 months without daily compliance requirements. Injections provide adjustable dosing with greater flexibility in dose changes, typically on a weekly or biweekly schedule. Pellets are preferred by many women who value convenience and level stability. Injections are preferred by patients who want more control over dose adjustments, particularly during the optimization phase of the protocol.

Can testosterone therapy help women's libido?

Testosterone is a primary driver of libido in women as well as men. Lab-confirmed low testosterone combined with symptoms of reduced libido, low energy, difficulty with orgasm, or reduced sexual motivation is a clear indication for testosterone supplementation. Low-dose testosterone correction for women is associated with significant improvements in sexual function and overall well-being in the clinical literature and in practice at Rebuild Regen.

---

When HRT Is Contraindicated or Requires Modification

Hormone replacement therapy is not appropriate in all circumstances. The following represent contexts where HRT is either contraindicated or requires significant protocol modification.

Active hormone-sensitive cancer: Women with active estrogen receptor-positive breast cancer or endometrial cancer are not candidates for systemic estrogen therapy. Oncology clearance and specific oncologist guidance is required before any hormone protocol is considered.

History of estrogen-sensitive cancer: Prior breast cancer with ER-positive pathology is a relative contraindication that requires individualized risk-benefit discussion. Some women with prior cancer and severe menopausal symptoms choose HRT with oncology involvement in the decision. Non-hormonal symptom management options are discussed first.

Active unresolved thrombosis or high thrombotic risk: Oral estrogen increases clotting risk through first-pass liver metabolism. For women with personal history of DVT, pulmonary embolism, or known thrombophilia, transdermal estrogen (cream, gel, or patch) bypasses liver metabolism and does not carry the same thrombotic risk. Oral HRT is avoided; transdermal routes require individual risk assessment.

Unexplained vaginal bleeding: Active unexplained uterine bleeding must be evaluated and explained before HRT is initiated. Endometrial pathology must be excluded.

Severe uncontrolled hypertension or cardiovascular disease in late menopause: The timing of HRT initiation affects the cardiovascular risk-benefit calculation. Women who are more than 10 years past menopause onset or over age 60 with established cardiovascular disease require a more careful risk assessment before beginning HRT.

Elizabeth Celestin navigates these considerations with clinical transparency. Women who are not ideal candidates are not turned away without options; they receive honest guidance on modified protocols, non-hormonal alternatives, and when a referral to a specialist is the appropriate next step.

Schedule a consultation: (954) 953-4208 | Rebuild Regen Medical Clinic, 3320 N Federal Hwy #101, Lighthouse Point, FL 33064.